Literature DB >> 26648141

let-7a and its target, insulin-like growth factor 1 receptor, are differentially expressed in recurrent prostate cancer.

Bing Tian1, Nannan Huo1, Meng Li1, Yong Li1, Zhongzhou He2.   

Abstract

Prostate cancer (PCa) is the most common malignancy in males worldwide. Approximately 30% of those patients who received radical prostatectomy developed clinical recurrence accompanied by elevated serum prostate‑specific antigen levels. Although knowledge regarding the development of PCa has been significantly improved, the molecular mechanism underlying recurrence remains largely unknown. The objective of the present study was to identify the differentially expressed microRNAs (miRNAs) in recurrent PCa to explore the possible involvement of miRNAs in the relapse. The expression of 6 miRs that have been previously reported to be downregulated in PCa stem cells were examined in a total of 32 recurrent and 36 non‑recurrent PCa samples, and let‑7a was substantially decreased in the recurrent PCa. Using the online prediction tools, let‑7a was identified to virtually target insulin‑like growth factor 1 receptor (IGF1R). IGF1R as a target of let‑7a was subsequently validated using the luciferase assay. Exogenous expression of let‑7a suppressed the expression of IGF1R, and reduced the proliferation of PCa cells by introducing apoptosis to the cells. In conclusion, the present data demonstrated a possible involvement of let‑7a in the pathogenesis of recurrent PCa, and it may be a potential target of the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26648141     DOI: 10.3892/ijmm.2015.2357

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

Review 1.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

2.  Upregulated microRNA let-7a accelerates apoptosis and inhibits proliferation in uterine junctional zone smooth muscle cells in adenomyosis under conditions of a normal activated hippo-YAP1 axis.

Authors:  Jun-Hua Huang; Hua Duan; Sha Wang; Yi-Yi Wang; Cheng-Xiao Lv
Journal:  Reprod Biol Endocrinol       Date:  2021-06-03       Impact factor: 5.211

3.  Physical Activity Modulates miRNAs Levels and Enhances MYOD Expression in Myoblasts.

Authors:  Luca Dalle Carbonare; Gianluigi Dorelli; Veronica Li Vigni; Arianna Minoia; Jessica Bertacco; Samuele Cheri; Michela Deiana; Giulio Innamorati; Mattia Cominacini; Cantor Tarperi; Federico Schena; Monica Mottes; Maria Teresa Valenti
Journal:  Stem Cell Rev Rep       Date:  2022-03-22       Impact factor: 6.692

Review 4.  Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals.

Authors:  Alessandra Bosutti; Fabrizio Zanconati; Gabriele Grassi; Barbara Dapas; Sabina Passamonti; Bruna Scaggiante
Journal:  Anticancer Agents Med Chem       Date:  2016       Impact factor: 2.505

Review 5.  Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Authors:  Zhongwei Zhao; Carsten Stephan; Sabine Weickmann; Monika Jung; Glen Kristiansen; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

6.  MiR-93/miR-375: Diagnostic Potential, Aggressiveness Correlation and Common Target Genes in Prostate Cancer.

Authors:  Ewa Ciszkowicz; Paweł Porzycki; Małgorzata Semik; Ewa Kaznowska; Mirosław Tyrka
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

7.  Association of Genetic Polymorphisms in MicroRNAs With Type 2 Diabetes Mellitus in a Chinese Population.

Authors:  Zaihan Zhu; Yanfen Zhang; Ruocen Bai; Ru Yang; Zhongyan Shan; Chunyan Ma; Jun Yang; Dandan Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-08       Impact factor: 5.555

8.  Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.

Authors:  Geetha Nalairndran; Ivy Chung; Azad Hassan Abdul Razack; Felicia Fei-Lei Chung; Ling-Wei Hii; Wei-Meng Lim; Chin King Looi; Chun-Wai Mai; Chee-Onn Leong
Journal:  J Cell Mol Med       Date:  2021-07-28       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.